HRP20260351T1 - C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksane - Google Patents
C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksaneInfo
- Publication number
- HRP20260351T1 HRP20260351T1 HRP20260351TT HRP20260351T HRP20260351T1 HR P20260351 T1 HRP20260351 T1 HR P20260351T1 HR P20260351T T HRP20260351T T HR P20260351TT HR P20260351 T HRP20260351 T HR P20260351T HR P20260351 T1 HRP20260351 T1 HR P20260351T1
- Authority
- HR
- Croatia
- Prior art keywords
- c5ar1
- taxane
- inhibitors
- treatment
- hypersensitivity reactions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21163292.2A EP4059497A1 (en) | 2021-03-17 | 2021-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| EP21217382 | 2021-12-23 | ||
| EP22716203.9A EP4308114B1 (en) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| PCT/EP2022/057007 WO2022195017A1 (en) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20260351T1 true HRP20260351T1 (hr) | 2026-04-24 |
Family
ID=81307212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20260351TT HRP20260351T1 (hr) | 2021-03-17 | 2022-03-17 | C5ar1 inhibitori za liječenje reakcija preosjetljivosti na taksane |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240180888A1 (https=) |
| EP (1) | EP4308114B1 (https=) |
| JP (1) | JP2024512472A (https=) |
| BR (1) | BR112023018826A2 (https=) |
| CA (1) | CA3212816A1 (https=) |
| DK (1) | DK4308114T3 (https=) |
| FI (1) | FI4308114T3 (https=) |
| HR (1) | HRP20260351T1 (https=) |
| IL (1) | IL305727A (https=) |
| LT (1) | LT4308114T (https=) |
| WO (1) | WO2022195017A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025193888A1 (en) * | 2024-03-14 | 2025-09-18 | Vanqua Bio, Inc. | Pyridazinone c5ar1 antagonists and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261275A (zh) * | 1997-05-27 | 2000-07-26 | 巴克·诺顿药物有限公司 | 给予病人口服紫杉烷类药物的方法和组合物 |
| CA2298475A1 (en) * | 1997-10-31 | 1999-05-14 | Walter Reed Army Institute Of Research | Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
| JP2003512443A (ja) * | 1999-10-27 | 2003-04-02 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | タキサンをヒト患者に経口投与するための方法及び組成物 |
| ES2597843T3 (es) | 2005-11-24 | 2017-01-23 | Dompé Farmaceutici S.P.A. | Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
-
2022
- 2022-03-17 BR BR112023018826A patent/BR112023018826A2/pt unknown
- 2022-03-17 WO PCT/EP2022/057007 patent/WO2022195017A1/en not_active Ceased
- 2022-03-17 FI FIEP22716203.9T patent/FI4308114T3/fi active
- 2022-03-17 US US18/282,357 patent/US20240180888A1/en active Pending
- 2022-03-17 CA CA3212816A patent/CA3212816A1/en active Pending
- 2022-03-17 LT LTEPPCT/EP2022/057007T patent/LT4308114T/lt unknown
- 2022-03-17 IL IL305727A patent/IL305727A/en unknown
- 2022-03-17 HR HRP20260351TT patent/HRP20260351T1/hr unknown
- 2022-03-17 EP EP22716203.9A patent/EP4308114B1/en active Active
- 2022-03-17 DK DK22716203.9T patent/DK4308114T3/da active
- 2022-03-17 JP JP2023556979A patent/JP2024512472A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240180888A1 (en) | 2024-06-06 |
| LT4308114T (lt) | 2026-03-25 |
| DK4308114T3 (da) | 2026-03-23 |
| FI4308114T3 (fi) | 2026-03-25 |
| BR112023018826A2 (pt) | 2024-03-12 |
| WO2022195017A1 (en) | 2022-09-22 |
| EP4308114B1 (en) | 2026-02-11 |
| JP2024512472A (ja) | 2024-03-19 |
| CA3212816A1 (en) | 2022-09-22 |
| EP4308114A1 (en) | 2024-01-24 |
| IL305727A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| EP3595672C0 (en) | COMPOUNDS FOR USE IN METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| EP4352042A4 (en) | COMPOUNDS FOR THE TREATMENT OF SARS | |
| HUE049591T2 (hu) | Makrociklusos MCL-1 inhibitorok rák kezelésére | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| PL3455258T3 (pl) | Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1 | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| SI3426250T1 (sl) | Zdravljenje pacienta s substratnim zdravilom CYP3A4 s kontraindikacijo za sočasno dajanje z močnim zaviralcem CYP3A4 | |
| SI3773593T1 (sl) | Zdravljenje hidradenitisa suppurative z zaviralci jak | |
| IL261015B (en) | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | |
| EP3464643A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| EP3589289A4 (en) | INHIBITION OF SMARCA2 FOR THE TREATMENT OF CANCER | |
| CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| IL272321A (en) | Methods and compositions for treatment of amyloid deposition diseases | |
| EP4337329A4 (en) | COMBINATIONS FOR CANCER TREATMENT | |
| SI3573620T1 (sl) | Sestavki za zdravljenje hipertenzije | |
| IL283659A (en) | Methods for treating cancer resistant to cdk4/6 inhibitors | |
| SI3833665T1 (sl) | Diazabiciklooktanoni kot zaviralci serinskih beta-laktamaz | |
| IL282041A (en) | Egfr inhibitors for treating keratodermas | |
| EP3852877A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINITIS PIGMENTOSA | |
| SI3886799T1 (sl) | Sestavki za zdravljenje izpadanja las | |
| EP4426682A4 (en) | SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | |
| IL291424A (en) | Use of dkk-1 inhibitors for treating cancer |